UBS Group’s Lux Health Tech Acquisition Corp. Units LUXAU Stock Holding History

UBS Group’s Portfolio LUXAU Stock Details LUXAU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-10,835	Closed	-$108K	–	11892
2022 Q3	$108K	Sell	10,835 -2,459	-18%	-$24.5K	﹤0.01%	5643
2022 Q2	$132K	Buy	13,294 +1,820	+16%	+$18.1K	﹤0.01%	5221
2022 Q1	$115K	Sell	11,474 -276	-2%	-$2.75K	﹤0.01%	5810
2021 Q4	$118K	Buy	11,750 +144	+1%	+$1.47K	﹤0.01%	6155
2021 Q3	$118K	Buy	11,606 +45	+0.4%	+$459	﹤0.01%	5716
2021 Q2	$119K	Buy	11,561 +1,561	+16%	+$16.3K	﹤0.01%	5754
2021 Q1	$107K	Buy	10,000 +9,536	+2,055%	+$113K	﹤0.01%	5917
2020 Q4	$5K	Buy	+464	New	+$4.98K	﹤0.01%	7865

UBS Group's LUXAU Position: Q4 2022 in Review

UBS Group sold out of Lux Health Tech Acquisition Corp. Units (LUXAU) in Q4 2022, closing a stake of 10,835 shares — an estimated $108K sold.

UBS Group first reported a position in LUXAU in Q4 2020 and held it in 8 quarters. The position peaked at $132K in Q2 2022. 0 funds tracked by Wall St. Rank hold LUXAU as of Q4 2022.

UBS Group reported no remaining Lux Health Tech Acquisition Corp. Units position as of Q4 2022 after selling out during the quarter.
UBS Group sold 10,835 Lux Health Tech Acquisition Corp. Units shares in Q4 2022, an estimated $108K.
UBS Group first reported a position in Lux Health Tech Acquisition Corp. Units in Q4 2020 and held it in 8 quarters.
UBS Group's Lux Health Tech Acquisition Corp. Units position peaked at $132K in Q2 2022.
0 funds tracked by Wall St. Rank held Lux Health Tech Acquisition Corp. Units as of Q4 2022.

Based on UBS Group's 13F filing for Q4 2022, filed 8 Feb 2023.